http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A CONSIDERATION FOR DELTA-SIGMA MODULATOR IN MULTI-CHANNEL MEASUREMENT SYSTEMS
Atsushi ASADA,Satoshi HIRANO,Tomio GOTO,Masaru SAKURAI,Shogo MIURA,Daijyu ITAGAKI 대한전자공학회 2009 ITC-CSCC :International Technical Conference on Ci Vol.2009 No.7
In this papar, we have examined reproduction of waveform and stability that needs to be cleared in order to introduce the delta-sigma modulator into the multi-channel measurement systems. Our study has proved that the delta-sigma modulator can be applied to the multi-channel measurement system.
Astrochemical Properties of Planck Cold Clumps
Tatematsu, Ken’ichi,Liu, Tie,Ohashi, Satoshi,Sanhueza, Patricio,Nguyê,̃,n Lu’o’, Quang,Hirota, Tomoya,Liu, Sheng-Yuan,Hirano, Naomi,Choi, Minho,Kang, Miju,A.Thompson, Mark,Fuller, Gary,Wu, Y Published by the University of Chicago Press for t 2017 The Astrophysical journal Supplement series Vol.228 No.2
<P>We observed 13 Planck cold clumps with the James Clerk Maxwell Telescope/SCUBA-2 and with the Nobeyama 45 m radio telescope. The N2H+ distribution obtained with the Nobeyama telescope is quite similar to SCUBA-2 dust distribution. The 82 GHz HC3N, 82 GHz CCS, and 94 GHz CCS emission are often distributed differently with respect to the N2H+ emission. The CCS emission, which is known to be abundant in starless molecular cloud cores, is often very clumpy in the observed targets. We made deep single-pointing observations in DNC, (HNC)-C-13, N2D+, and cyclic-C3H2 toward nine clumps. The detection rate of N2D+ is 50%. Furthermore, we observed the NH3 emission toward 15 Planck cold clumps to estimate the kinetic temperature, and confirmed that most targets are cold (less than or similar to 20 K). In two of the starless clumps we observed, the CCS emission is distributed as it surrounds the N2H+ core (chemically evolved gas), which resembles the case of L1544, a prestellar core showing collapse. In addition, we detected both DNC and N2D+. These two clumps are most likely on the verge of star formation. We introduce the chemical evolution factor (CEF) for starless cores to describe the chemical evolutionary stage, and analyze the observed Planck cold clumps.</P>
Naohiro Sekiguchi,Airi Hamano,Tomoko Kitagawa,Yuya Kurihara,Kenichi Ito,Miwa Kurimoto,Kozo Watanabe,Kazuhiko Hirano,Satoshi Noto,Kazuaki Yamada,Naoki Takezako 대한혈액학회 2018 Blood Research Vol.53 No.2
Background Waldenström Macroglobulinemia (WM) is a rare subtype of indolent B-cell lymphoma, and prospective randomized studies on WM are scarce. The R-CHOP therapy [rituximab (R), cyclophosphamide, hydroxy-doxorubicin, vincristine, and prednisone] is a popular and recommended regimen for primary therapy, prescribed by several treatment guide-lines for WM. However, treatment with R-CHOP is accompanied by severe myelosup-pression and high rates of peripheral neuropathy. Therefore, we retrospectively evaluated the efficacy and toxicity of half-dose CHOP combined with R as a primary therapy for WM. Methods Patients with untreated symptomatic WM, treated at the Disaster Medical Center be-tween April 2011 and September 2016, were retrospectively analyzed after admin-istration of 6 cycles of half-dose R-CHOP for every 3 weeks. The response, median time to response, best response, progression-free survival, overall survival, and toxicities were evaluated. Results Of the 20 WM patients analyzed, 16 (80%) received half-dose R-CHOP without vincris-tine, and 13 (65%) responded to the treatment. With a median follow-up duration of 26.3 months, the 2-year progression-free survival and 2-year overall survival rates were 70 and 93.3%, respectively. The median time to response and best response were 6 and 9.9 weeks, respectively. Grade 3/4 leukocytopenia, neutropenia, febrile neutropenia, and Grade 1 peripheral neuropathy developed in 32, 37, 0, and 21% of patients, respectively. Conclusion The half-dose R-CHOP is an effective and well-tolerated primary therapy for WM. To the best of our knowledge, this is the first study reporting the use of a reduced-dose R-CHOP regimen for the primary treatment of WM.
Naohiro Sekiguchi,Airi Hamano,Tomoko Kitagawa,Yuya Kurihara,Kenichi Ito,Miwa Kurimoto,Kozo Watanabe,Kazuhiko Hirano,Satoshi Noto,Kazuaki Yamada,Naoki Takezako 대한혈액학회 2018 Blood Research Vol.53 No.2
Background Waldenström Macroglobulinemia (WM) is a rare subtype of indolent B-cell lymphoma, and prospective randomized studies on WM are scarce. The R-CHOP therapy [rituximab (R), cyclophosphamide, hydroxy-doxorubicin, vincristine, and prednisone] is a popular and recommended regimen for primary therapy, prescribed by several treatment guide-lines for WM. However, treatment with R-CHOP is accompanied by severe myelosup-pression and high rates of peripheral neuropathy. Therefore, we retrospectively evaluated the efficacy and toxicity of half-dose CHOP combined with R as a primary therapy for WM. Methods Patients with untreated symptomatic WM, treated at the Disaster Medical Center be-tween April 2011 and September 2016, were retrospectively analyzed after admin-istration of 6 cycles of half-dose R-CHOP for every 3 weeks. The response, median time to response, best response, progression-free survival, overall survival, and toxicities were evaluated. Results Of the 20 WM patients analyzed, 16 (80%) received half-dose R-CHOP without vincris-tine, and 13 (65%) responded to the treatment. With a median follow-up duration of 26.3 months, the 2-year progression-free survival and 2-year overall survival rates were 70 and 93.3%, respectively. The median time to response and best response were 6 and 9.9 weeks, respectively. Grade 3/4 leukocytopenia, neutropenia, febrile neutropenia, and Grade 1 peripheral neuropathy developed in 32, 37, 0, and 21% of patients, respectively. Conclusion The half-dose R-CHOP is an effective and well-tolerated primary therapy for WM. To the best of our knowledge, this is the first study reporting the use of a reduced-dose R-CHOP regimen for the primary treatment of WM.